Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Changes in the use of HIV antiretroviral resistance testing in a large cohort of U.S. patients, 1999 to 2006.

Buchacz K, Baker RK, Young B, Brooks JT; HIV Outpatient Study (HOPS) Investigators.

J Acquir Immune Defic Syndr. 2010 Apr;53(5):625-32. doi: 10.1097/QAI.0b013e3181bf1dd2.

PMID:
19841587
2.

The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study.

Palella FJ Jr, Armon C, Buchacz K, Cole SR, Chmiel JS, Novak RM, Wood K, Moorman AC, Brooks JT; HOPS (HIV Outpatient Study) Investigators.

Ann Intern Med. 2009 Jul 21;151(2):73-84.

PMID:
19620160
3.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
4.

Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire.

Adjé-Touré C, Celestin B, Hanson D, Roels TH, Hertogs K, Larder B, Diomande F, Peeters M, Eholié S, Lackritz E, Chorba T, Nkengasong JN.

AIDS. 2003 Jul;17 Suppl 3:S23-9.

PMID:
14565606
5.

The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities.

Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM Jr, LaLota M, Dickinson G, Schwarcz S, Torian L, Wendell D, Paul S, Goza GA, Ruiz J, Boyett B, Kaplan JE.

J Infect Dis. 2004 Jun 15;189(12):2174-80. Epub 2004 May 21.

PMID:
15181563
6.

Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel.

Wegner SA, Brodine SK, Mascola JR, Tasker SA, Shaffer RA, Starkey MJ, Barile A, Martin GJ, Aronson N, Emmons WW, Stephan K, Bloor S, Vingerhoets J, Hertogs K, Larder B.

AIDS. 2000 May 26;14(8):1009-15.

PMID:
10853983
7.

Antiretroviral drug resistance among antiretroviral-naïve persons with recent HIV infection in Thailand.

Apisarnthanarak A, Jirayasethpong T, Sa-nguansilp C, Thongprapai H, Kittihanukul C, Kamudamas A, Tungsathapornpong A, Mundy LM.

HIV Med. 2008 May;9(5):322-5. doi: 10.1111/j.1468-1293.2008.00562.x.

8.

HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?

Uy J, Brooks JT, Baker R, Hoffman M, Moorman A, Novak R; HOPS Investigators.

Antivir Ther. 2007;12(6):957-62.

PMID:
17926650
9.

Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.

Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V; Red de Investigación en SIDA.

J Med Virol. 2005 Sep;77(1):23-8.

PMID:
16032728
10.
11.

Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.

Adjé-Touré CA, Cheingsong R, Garcìa-Lerma JG, Eholié S, Borget MY, Bouchez JM, Otten RA, Maurice C, Sassan-Morokro M, Ekpini RE, Nolan M, Chorba T, Heneine W, Nkengasong JN.

AIDS. 2003 Jul;17 Suppl 3:S49-54.

PMID:
14565609
12.

Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar years: a cohort study.

Bracciale L, Fanti I, Di Giambenedetto S, Colafigli M, Prosperi M, Bacarelli A, Santangelo R, Cattani P, Cauda R, De Luca A.

J Clin Virol. 2009 Nov;46(3):290-4. doi: 10.1016/j.jcv.2009.07.013. Epub 2009 Aug 21.

PMID:
19699675
13.

A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?

Simcock M, Sendi P, Ledergerber B, Keller T, Schüpbach J, Battegay M, Günthard HF; Swiss HIV Cohort Study.

Antivir Ther. 2006;11(3):305-14.

PMID:
16759046
14.
15.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
16.

Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy.

Vergne L, Kane CT, Laurent C, Diakhaté N, Gueye NF, Gueye PM, Sow PS, Faye MA, Liégeois F, Ndir A, Lanièce I, Peeters M, Ndoye I, Mboup S, Delaporte E.

AIDS. 2003 Jul;17 Suppl 3:S31-8.

PMID:
14565607
17.

Net benefits of resistance testing directed therapy compared with standard of care in HIV-infected patients with virological failure: A meta-analysis.

Ena J, Ruiz de Apodaca RF, Amador C, Benito C, Pasquau F.

Enferm Infecc Microbiol Clin. 2006 Apr;24(4):232-7.

PMID:
16725082
18.

Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.

Lafeuillade A, Poggi C, Hittinger G, Chadapaud S.

HIV Med. 2001 Oct;2(4):231-5.

19.

Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.

Machado ES, Lambert JS, Watson DC, Afonso AO, da Cunha SM, Nogueira SA, Caride E, Oliveira RH, Sill AM, DeVico A, Tanuri A.

J Clin Virol. 2004 May;30(1):24-31.

PMID:
15072750
20.

Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.

Pattery T, Verlinden Y, De Wolf H, Nauwelaers D, Van Baelen K, Van Houtte M, Mc Kenna P, Villacian J.

Intervirology. 2012;55(2):138-46. doi: 10.1159/000332013. Epub 2012 Jan 24.

PMID:
22286884

Supplemental Content

Support Center